Phibro Animal Health Lifts Full-Year Guidance on Robust Quarterly Performance

Phibro Animal Health US71742Q1067

Phibro Animal Health Corporation has raised its financial outlook for fiscal year 2026 following a second-quarter report that substantially exceeded market expectations. The company's improved forecast is attributed to a combination of strategic acquisition benefits and sustained organic growth within its core product segments.

In response to the strong quarterly results, management has issued an upward revision to its full-year projections. The company now anticipates revenue for fiscal 2026 to land between $1.45 billion and $1.50 billion. At the midpoint, this new range implies an approximate 14% year-over-year increase.

Profitability metrics were also adjusted upward. The forecast for adjusted EBITDA is now set at $245 million to $255 million, representing a significant 36% rise compared to the prior year. Furthermore, guidance for adjusted diluted earnings per share (EPS) was lifted to a range of $2.93 to $3.10, which would equate to growth of about 44%.

Second Quarter Highlights: A Detailed Look

The period, which concluded on December 31, 2025, saw Phibro generate revenue of $373.9 million. This figure marks a substantial 21% increase over the same quarter in the previous fiscal year.

Profitability saw even more dramatic improvement. Net income surged to $27.5 million, a stark contrast to the $3.2 million reported a year ago. On a per-share basis, adjusted diluted EPS climbed 58% to reach $0.87.

Key Second-Quarter and Forward-Looking Metrics:

• Q2 Revenue: $373.9 million (a 21% increase)
• Q2 Adjusted Diluted EPS: $0.87 (a 58% increase)
• Updated FY 2026 Revenue Guidance: $1.45 billion to $1.50 billion
• Quarterly Dividend Payout: $0.12 per share

Drivers of Growth and Shareholder Returns

Two primary factors fueled the quarter's outperformance. The integration of the MFA portfolio, acquired in late October 2024, contributed meaningful supplemental revenue. Concurrently, the company experienced continued organic expansion across its specialty nutrient and vaccine product lines in diverse geographic markets.

Management expressed confidence in the ongoing favorable market conditions for livestock producers, coupled with advancements in product innovation for animal health and nutrition, as the foundation for its upgraded annual forecast.

Shareholders will receive a direct benefit from the firm's robust financial position. A quarterly cash dividend of $0.12 per share has been declared, payable on March 25, 2026, to shareholders of record as of March 4, 2026. This consistent distribution underscores the company's stable cash flow generation.

@ boerse-global.de | US71742Q1067 PHIBRO